secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001213900-25-118989
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics CFO Jeffrey Ervin moves to full-time; gets $367.7K salary, $160K RSUs
--------------------------------------------------------------------------------

- CFO Jeffrey S. Ervin transitioned from part-time to full-time effective December 3, 2025 under new employment agreement.
- Annual base salary set at $367,700; eligible for annual bonus up to 30% of base salary.
- Granted restricted stock units valued at $160,000, vesting in equal installments over three years.
- Severance of six months base salary if terminated without cause, for good reason, or in connection with change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390025118989/0001213900-25-118989-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390025118989/ea0268404-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-118989

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer